Discontinuing or withholding primary prophylaxis against Mycobacterium avium in patients on successful antiretroviral combination therapy. The Swiss HIV Cohort Study

AIDS

Volumn 14, Issue 10, 2000, Pages 1409-1412

  Furrer, Hansjakob ^a   Telenti, Amalio ^b   Rossi, Marco ^b   Ledergerber, Bruno ^b  

^a UNIVERSITY OF BERN   (Switzerland)

^b NONE

Author keywords

Antiretroviral combination therapy; CD4 cell count; Cohort study; Discontinuation of prophylaxis; HIV; Mycobacterium avium; Prophylaxis

Indexed keywords

ANTIMYCOBACTERIAL AGENT; ANTIRETROVIRUS AGENT; CD4 ANTIGEN;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; FOLLOW UP; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INCIDENCE; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MYCOBACTERIOSIS; MYCOBACTERIUM AVIUM; PRIORITY JOURNAL; PROSPECTIVE STUDY; STATISTICAL ANALYSIS; SWITZERLAND;

ADULT; AGED; AIDS-RELATED OPPORTUNISTIC INFECTIONS; ANTI-HIV AGENTS; CD4 LYMPHOCYTE COUNT; COHORT STUDIES; FEMALE; HIV INFECTIONS; HUMANS; MALE; MIDDLE AGED; MYCOBACTERIUM AVIUM-INTRACELLULARE INFECTION; SWITZERLAND;

EID: 0033926878     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-200007070-00014     Document Type: Article

References (23)

1. 1. Nightingale SD, Byrd LT, Southern PM, Jockusch JD, Cal SX, Wynne BA. Incidence of Mycobacterium avium-intracellulare complex bacteremia in human immunodeficiency virus-positive patients. J Infect Dis 1992, 165:1082-1085.
2. 2. Havlik JA, Jr, Horsburgh CR, Jr, Metchock B, Williams PP, Fann SA, Thompson SE, III. Disseminated Mycobacterium avium complex infection: clinical identification and epidemiologic trends. J Infect Dis 1992, 165:577-580.
3. 3. Hoover DR, Saah AJ, Bacellar H, et al. Clinical manifestations of AIDS in the era of pneumocystis prophylaxis. Multicenter AIDS Cohort Study. N Engl J Med 1993, 329:1922-1926.
4. 4. Low N, Pfluger D, Egger M, and the Swiss HIV Cohort Study. Disseminated Mycobacterium avium complex disease in the Swiss HIV Cohort Study: increasing incidence unchanged prognosis. AIDS 1997, 11:1165-1171.
5. 5. Public Health Service Task Force on Prophylaxis and Therapy of Mycobacterium avium Complex. Recommendations on prophylaxis and therapy for disseminated Mycobacterium avium complex disease in patients infected with human immunodeficiency virus. N Engl J Med 1993, 329:898-904.
6. 6. Havlir DV, Dubé MP, Sattler FR, et al. Prophylaxis against disseminated Mycobacterium avium complex with weekly azithromycin, daily rifabutin, or both. N Engl J Med 1996, 335:392-398.
7. 7. Nightingale SD, Cameron DW, Cordin FM, et al. Two controlled trials of rifabutin prophylaxis against Mycobacterium avium complex infection in AIDS [see comments]. N Engl J Med 1993, 329:828-833.
8. 8. Pierce MP, Crampton S, Henry D, et al. A randomized trial of clarithromycin as prophylaxis against disseminated Mycobacterium avium infection in patients with advanced acquired immunodeficiency syndrome. N Engl J Med 1996, 335:384-391.
9. 9. USPHS/IDSA Prevention of Opportunistic Infections Working Group. 1999 USPHS/IDSA guidelines for the prevention of opportunistic infections in persons infected with human immunodeficiency virus. MMWR 1999, 48(No.RR-10):1-66.
10. 10. Egger M, Hirschel B, Francioli P, et al. Impact of new antiretroviral combination therapies in HIV infected patients in Switzerland: prospective multicentre study. Br Med J 1997, 315:1194-1199.
11. 11. Palella FJ, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med 1998, 338:853-860.
12. 12. Ledergerber B, Egger M, Erard V, et al. AIDS-related opportunistic illnesses occurring after initiation of potent antiretroviral therapy: the Swiss HIV Cohort Study. J Am Med Assoc 1999, 282:2220-2226.
13. 13. Ledergerber B, von Overbeck J, Egger M, Lüthy R. The Swiss HIV cohort study: rationale, organization and selected baseline characteristics. Soz Präventivmed 1994, 39:387-394.
14. 14. Centers for disease control. 1993 Classification system for HIV infection and expanded surveillance case definition for acquired immunodeficiency syndrome (AIDS) among adolescents and adults. MMWR 1992, 41(RR-17):1-19.
15. 15. Li TS, Tubiana R, Katlama C, Calvez V, Ait Mohand H, Autran B. Long-lasting recovery in CD4 T-cell function and viral load reduction after highly active antiretroviral therapy in advanced HIV-1 disease. Lancet 1998, 351:1682-1686.
16. 16. Wendland T, Furrer H, Vernazza P, et al. HAART in HIV-infected patients: restoration of antigen-specific CD4 T-cell responses in vitro is correlated to CD4-memory T-cell reconstitution, whereas improvement in delayed type hypersensitivity is related to a decrease in viremia. AIDS 1999, 13:1857-1862.
17. 17. Furrer H, Egger M, Opravil M, et al. Discontinuation of primary prophylaxis against Pneumocystis carinii pneumonia in HIV-1 infected adults treated with combination antiretroviral therapy. N Engl J Med 1999, 340:1301-1306.
18. 18. Weverling GJ, Mocroft A, Ledergerber B, et al. Discontinuation of Pneumocystis carinii pneumonia prophylaxis after start of highly active antiretroviral therapy in HIV-1 infection. EuroSIDA Study Group. Lancet 1999, 353:1293-1298.
19. 19. Furrer H, Jacobson MA, Reiss P, Telenti A. Discontinuation of prophylaxis against opportunistic infections in HIV-infected persons receiving potent combination antiretroviral therapy. AIDS Rev 1999, 1:183-192.
20. 20. Centers for disease control and prevention. 1999 USPHS/IDSA guidelines for the prevention of opportunistic infections in persons infected with human immunodeficiency virus. U.S. Public Health Service (USPHS) and Infectious Diseases Society of America (IDSA). MMWR 1999, 48(RR-10):1-66.
21. 21. Race EM, Adelson-Mitty J, Kriegel GR, et al. Focal mycobacterial lymphadenitis following initiation of protease-inhibitor therapy in patients with advanced HIV-1 disease. Lancet 1998, 351:252-255.
22. 22. Foudraine NA, Hovenkamp E, Notermans DW, et al. Immunopathology as a result of highly active antiretroviral therapy in HIV-1-infected patients. AIDS 1999, 13:177-184.
23. 23. Sepkowitz KA. Effect of HAART on natural history of AIDS-related opportunistic disorders. Lancet 1998, 351:228-229.